机译:enasidenib:第一突变体IDH2抑制剂用于治疗难治性和复发复发急性髓性白血病
Department of Pharmaceutical Chemistry &
Analysis Indo-Soviet Friendship College of Pharmacy;
Department of Pharmaceutical Chemistry &
Analysis Indo-Soviet Friendship College of Pharmacy;
Bio-Organic Chemistry Division Indian Institute of Integrative Medicine (CSIR);
University Centre of Excellence in Research Baba Farid University of Health Sciences Faridkot;
Department of Chemistry Maharishi Markandeshwar (Deemed to be University);
Acute myeloid leukemia; isocitrate dehydrogenase 2; enasidenib; R-2-hydroxyglutarate; IDH2 inhibitor; bone marrow;
机译:Enasidenib,突变体IDH2蛋白的靶向抑制剂,用于治疗复发或难治性急性髓鞘性白血病
机译:enasidenib:第一突变体IDH2抑制剂用于治疗难治性和复发复发急性髓性白血病
机译:Enasidenib在突变体IDH2中复发或难治性急性髓性白血病
机译:计算源自骨髓移植后急性髓性白血病患者复发风险的细胞学图像标志物
机译:FLT3抑制剂对FLT3-ITD突变急性髓性白血病标准治疗的比较
机译:依那替尼治疗突变IDH2复发或难治性急性髓细胞性白血病
机译:oncometabolic造成的影响:批准的IDH1和IDH2抑制剂在复发或难治性急性髓性白血病中